Author:
del Campo J M,Hitt R,Sebastian P,Carracedo C,Lokanatha D,Bourhis J,Temam S,Cupissol D,De Raucourt D,Maroudias N,Nutting C M,Compton N,Midwinter D,Downie L,Biswas-Baldwin N,El-Hariry I,Harrington K J
Publisher
Springer Science and Business Media LLC
Reference49 articles.
1. Abidoye OO, Cohen EE, Wong SJ, Kozloff MF, Nattam SR, Stenson KM, Blair EA, Day S, Dancey JE, Vokes EE (2006) A phase II study of lapatinib (GW572016) in recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN). J Clin Oncol 24 (suppl): 5568
2. Agulnik M, da Cunha Santos G, Hedley D, Nicklee T, Dos Reis PP, Ho J, Pond GR, Chen H, Chen S, Shyr Y, Winquist E, Soulieres D, Chen EX, Squire JA, Marrano P, Kamel-Reid S, Dancey J, Siu LL, Tsao MS (2007) Predictive and pharmacodynamic biomarker studies in tumor and skin tissue samples of patients with recurrent or metastatic squamous cell carcinoma of the head and neck treated with erlotinib. J Clin Oncol 25 (16): 2184–2190
3. Ang KK, Berkey BA, Tu X, Zhang HZ, Katz R, Hammond EH, Fu KK, Milas L (2002) Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 62 (24): 7350–7356
4. Banerji U, de Bono J, Judson I, Kaye S, Workman P (2008) Biomarkers in early clinical trials: the committed and the skeptics. Clin Cancer Res 14 (8): 2512–2514
5. Bartelink H, Begg A, Martin JC, van Dijk M, van ‘t Veer L, van der Vaart P, Verheij M (1999) Towards prediction and modulation of treatment response. Radiother Oncol 50 (1): 1–11
Cited by
101 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献